State of Wisconsin Investment Board Acquires New Position in bluebird bio, Inc. (BLUE)
State of Wisconsin Investment Board acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 31,000 shares of the biotechnology company’s stock, valued at approximately $3,257,000. State of Wisconsin Investment Board owned about 0.08% of bluebird bio as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC increased its stake in shares of bluebird bio by 0.6% in the 1st quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock worth $556,918,000 after acquiring an additional 37,742 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of bluebird bio in the 1st quarter worth $858,000. Winfield Associates Inc. increased its stake in shares of bluebird bio by 6.1% in the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after acquiring an additional 162 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in shares of bluebird bio in the 4th quarter worth $703,000. Finally, Alliancebernstein L.P. increased its stake in shares of bluebird bio by 50.1% in the 1st quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock worth $7,805,000 after acquiring an additional 28,640 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/04/state-of-wisconsin-investment-board-acquires-new-position-in-bluebird-bio-inc-blue.html.
bluebird bio, Inc. (NASDAQ:BLUE) opened at 130.85 on Monday. The stock’s market capitalization is $5.97 billion. bluebird bio, Inc. has a 12-month low of $37.05 and a 12-month high of $133.10. The stock’s 50 day moving average price is $98.27 and its 200-day moving average price is $93.20.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.07. The business had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s revenue for the quarter was up 977.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.59) earnings per share. Analysts expect that bluebird bio, Inc. will post ($6.82) earnings per share for the current year.
A number of brokerages have issued reports on BLUE. Cowen and Company reaffirmed an “outperform” rating on shares of bluebird bio in a research note on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $135.00 target price (up from $121.00) on shares of bluebird bio in a research note on Friday. BidaskClub raised bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Morgan Stanley reaffirmed an “equal weight” rating and issued a $105.00 target price (up from $91.00) on shares of bluebird bio in a research note on Wednesday, June 14th. Finally, Cantor Fitzgerald set a $39.00 target price on bluebird bio and gave the stock a “sell” rating in a research note on Saturday, June 24th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $102.68.
In related news, Director Daniel Lynch sold 2,500 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $120.03, for a total value of $300,075.00. Following the completion of the transaction, the director now directly owns 5,300 shares in the company, valued at $636,159. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Davidson sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $92.37, for a total value of $277,110.00. Following the completion of the transaction, the insider now owns 18,977 shares of the company’s stock, valued at $1,752,905.49. The disclosure for this sale can be found here. Insiders sold 104,023 shares of company stock valued at $11,148,508 over the last quarter. Insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.